Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

By LabMedica International staff writers
Posted on 17 Nov 2026

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. More...

However, testing only one or two genes can miss actionable tumor alterations, highlighting the value of broader molecular profiling before treatment. A new study suggests that broad-based genomic sequencing before first-line therapy is associated with longer survival, supporting its potential role in guiding treatment decisions.

Researchers at Emory University School of Medicine and Winship Cancer Institute evaluated the impact of broad-based genomic sequencing on treatment outcomes in patients with advanced non-small cell lung cancer. Unlike limited testing that examines only one or two biomarkers, broad-based sequencing analyzes dozens or hundreds of genes simultaneously, potentially identifying a wider range of actionable tumor alterations to guide targeted therapy selection.

The study analyzed real-world data from the Flatiron Health Research Database, including more than 35,000 patients treated at community and academic oncology practices across the United States between 2016 and 2022. Researchers compared outcomes among patients who underwent broad-based genomic sequencing before first-line treatment with those who received more limited biomarker testing.

Patients who underwent broad-based genomic sequencing before first-line therapy had an average overall survival approximately two months longer than those receiving limited testing. The approach was also associated with modest improvements in progression-free survival. Additionally, 19% of patients in the broad-based sequencing group received targeted therapy, compared with 16% in the limited testing group. The findings were published in the November 2026 issue of the Journal of the National Comprehensive Cancer Network.

The results support existing National Comprehensive Cancer Network (NCCN) guidelines recommending broad-based genomic sequencing for patients with advanced or metastatic non-small cell lung cancer. Relevant biomarkers include EGFR, ALK, ROS1, KRAS G12C, MET, RET, and BRAF, which can help identify patients eligible for targeted treatments. The findings, also discussed in commentary from City of Hope, highlight the potential clinical value of comprehensive molecular profiling before treatment initiation.

“Our findings and prior work suggest broad-based genomic testing should be the default for patients with advanced lung cancer and should ideally happen prior to the administration of first-line therapy. The right test, done early, can open doors to treatments that might otherwise be missed,” said Ravi B. Parikh, M.D., M.P.P., of Emory University School of Medicine and Winship Cancer Institute.

Related Links
Emory University School of Medicine
Winship Cancer Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.